Cannabidiol-associated hepatotoxicity: A systematic review and meta-analysis.

Lindsay A LoApril ChristiansenLauren EadieJustin C StricklandDavid D KimMichael BoivinAlasdair M BarrCaroline A MacCallum

Published in: Journal of internal medicine (2023)

Cannabidiol-associated liver enzyme elevations and DILI meet the criteria of common adverse drug events. Clinicians are encouraged to screen for cannabidiol use and monitor liver function in patients at increased risk.

Keyphrases

adverse drug
drug induced
electronic health record
palliative care
high throughput
emergency department